HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse

Annals of Surgical Oncology

Volumn 21, Issue 3, 2014, Pages 955-962

  Braicu, Elena Ioana ^a   Chekerov, Radoslav ^a   Richter, Rolf ^a   Pop, Carmen ^a   Nassir, Mani ^a   Loefgren, Hanna ^a   Stamatian, Florin ^b   Muallem, Mustafa Zelal ^a   Hall, Christina ^c   Fotopoulou, Christina ^a   Sehouli, Jalid ^a   Pietzner, Klaus ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c FUJIREBIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN EPIDIDYMIS SECRETORY PROTEIN 4; PLATINUM; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CYTOREDUCTIVE SURGERY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDIDYMIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 84896863168     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3347-1     Document Type: Article

References (31)

1. Vernooij F, Heintz AP, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. J Natl Cancer Inst. 2008;100:399-406.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol. 1997;24:S2-13-S2-16.
3. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59.
4. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390-6.
5. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-4.
6. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424-7.
7. Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, et al. Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol. 2010;102:656-62.
8. Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, et al. Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol. 2011;18:49-57.
9. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21:289-95.
10. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847-53.
11. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238:375-85.
12. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402-8.
13. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196-201.
14. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-6.
15. Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280-8.
16. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer. 2011;21:1040-7.
17. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy algorithm. Br J Cancer. 2011;104:863-70.
18. Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, et al. Preoperative HE4 xpression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128:245-51.
19. Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128:579-83.
20. Sehouli J, Konsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, et al. ["IMO" - intraoperative mapping of ovarian cancer]. Zentralbl Gynakol. 2003;125:129-35.
21. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16:496-500.
22. Chi DS, Sabbatini, P. Advanced ovarian cancer. Curr Treat Options Oncol. 2000;1:139-46.
23. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, et al. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010;101:13-7.
24. Mury D, Woelber L, Jung S, Eulenburg C, Choschzick M, Witzel I, et al. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol. 2011;137:1131-7.
25. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59-64.
26. Yoo SC, Yoon JH, Lyu MO, Kim WY, Chang SJ, Chang KH, et al. Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer. J Gynecol Oncol. 2008;19:169-72.
27. Kong SY, Han MH, Yoo HJ, Hwang JH, Lim MC, Seo SS, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1707-12.
28. Gil-Ibáñez B, Oskay-Özcelik G, Richter R, Fotopoulou C, Braicu EI, Neuhaus P, et al; Tumor Bank Ovarian Cancer Network (TOC); European Competence Centre for Ovarian Cancer (EKZE Berlin). Predictive factors in relapsed ovarian cancer for complete tumor resection. Anticancer Res. 2011;31:2583-7.
29. Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF. Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis. J Ovarian Res. 2013;6:49.
30. Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C. Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer. 2012;48:687-94.
31. Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol. 2010;36:1202-10.